LOVASTATIN PLUS PROBUCOL FOR PREVENTION OF RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY

Authors
OKEEFE JH STONE GW MCCALLISTER BD MADDEX C LIGON R KACICH RL KAHN J CAVERO PG HARTZLER GO MCCALLISTER BD
Citation
Jh. Okeefe et al., LOVASTATIN PLUS PROBUCOL FOR PREVENTION OF RESTENOSIS AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, The American journal of cardiology, 77(8), 1996, pp. 649
Citations number
7
Categorie Soggetti
Cardiac & Cardiovascular System
Journal title
The American journal of cardiology → ACNP
ISSN journal
00029149
Volume
77
Issue
8
Year of publication
1996
Database
ISI
SICI code
0002-9149(1996)77:8<649:LPPFPO>2.0.ZU;2-#
Abstract
We hypothesized that combination therapy inc luding lovastatin (for lo w-density lipoprotein [LDL] lowering) and probucol (for antioxidant ac tivity) may be useful in reducing or preventing restenosis and recurre nt coronary events after percutaneous transluminal coronary angioplast y (PTCA). The Angioplasty Plus Probucol/Lovastatin Evaluation (APPLE) trial was designed to test this hypothesis.